Ann: December 2024 Quarterly Activities Report & Appendix 4C, page-13

I only took a position a few months ago mate so can't comment much on the BoD, though given the SP performance I would guess "not great"

My speculation is the adjustments made to the eligibility criteria now means some savings will be had in recruitment, they can pull from the prior cohort that were previously turned down. AVE very high on the risk level, my thesis is this will fit the US Bobby narrative with easing on psychedelics and alternative drug programs (similar to my position in TYP).

I am more on the 'hopeium' front that they can achieve interim readout without a raise then any sound analysis.

Good luck mate!